Methotrexate (n = 228) | Etanercept (n = 223) | Combination (n = 231) | ||||
---|---|---|---|---|---|---|
Baseline | Week 52 | Baseline | Week 52 | Baseline | Week 52 | |
EQ-5D VAS, EuroQoL health status visual analogue scale; PGAD, patient global assessment; GHVAS, patient general health visual analogue scale. | ||||||
†p<0.01 for combination versus MTX; ‡,‡p<0.01 and p<0.05, respectively, for combination versus etanercept. | ||||||
EQ-5D VAS | 38.74 (35.74 to 41.73) | 63.66 (60.48 to 66.84) | 43.12 (40.07 to 46.17) | 66.75 (63.51 to 70.00) | 40.74 (37.77 to 43.71) | 72.71 (69.57 to 75.85)†‡ |
PGAD | 6.85 (6.61 to 7.09) | 3.95 (3.63 to 4.27) | 6.86 (6.61 to 7.10) | 3.83 (3.50 to 4.15) | 7.16 (6.92 to 7.40) | 2.88 (2.56 to 3.20)†‡ |
GHVAS | 68.88 (66.15 to 71.61) | 36.28 (33.09 to 39.46) | 68.96 (66.19 to 71.74) | 35.32 (32.08 to 38.56) | 70.02 (67.31 to 72.72) | 24.80 (21.65 to 27.94)†‡ |